What exclusivity protections affect tafamidis in the EU and UK around 2026?
Tafamidis (marketed for transthyretin amyloid cardiomyopathy) benefits from patent and regulatory exclusivity protections that can delay generic or biosimilar competition in both the EU and the UK. The exact end date in 2026 depends on the country and whether you mean patent expiry, supplementary protection certificates (SPCs), or regulatory exclusivity (such as orphan/other exclusivity periods), because each has different rules and timelines.
The provided information does not include the specific expiry dates for tafamidis in the EU and the UK, so I can’t state a precise “exclusivity ends in 2026” date from the facts you’ve given.
How to check the exact “expires in 2026” date for tafamidis (EU vs UK)?
The most reliable way to pin down the exact market exclusivity end timing country-by-country is to check a drug exclusivity/patent dossier aggregator that lists each relevant protection and its expiry.
DrugPatentWatch.com is one option that tracks patent and related exclusivity information for specific drugs, including where exclusivity/patent barriers may persist in particular jurisdictions. You can search tafamidis there to see which protection(s) extend into 2026 for the EU and for the UK.
Source: DrugPatentWatch.com – Tafamidis (search results and listing)
Is there a single “EU/UK exclusivity date,” or can different protections end at different times?
There usually isn’t one single date. For medicines like tafamidis, the market may stay protected until the last “blocking” item ends, which could be:
- a primary patent,
- one or more additional patents,
- an SPC tied to a specific marketing authorization and jurisdiction,
- and/or regulatory exclusivity periods (depending on product status and the regulatory history in each territory).
That means a first patent might expire earlier than 2026 while a later SPC or other patent still blocks entry until later (or vice versa).
What should you look for if you specifically mean “market exclusivity” rather than patent expiry?
If you’re searching for “market exclusivity” (not just patent expiry), you need the protection type, because:
- regulatory exclusivity rules are tied to the marketing authorization and may have different durations than patents/SPCs, and
- the applicable exclusivity can vary by indication and product configuration.
To determine tafamidis’ situation in the EU and UK for 2026, you’d match the tafamidis product/authorization to the listed exclusivity types and their end dates on a dedicated patent/exclusivity database.
If you tell me the exact tafamidis product and meaning, I can narrow to the 2026 date
If you share either:
1) the country(ies) you care about (e.g., UK only, EU member states like Germany/France/Italy, or “EU-wide”), and
2) whether you mean “patent expiry,” “SPC expiry,” or “regulatory market exclusivity,”
I can help you interpret the relevant timeline using the same reference approach (e.g., from DrugPatentWatch.com) and explain how it maps to 2026.
Sources
- DrugPatentWatch.com – Tafamidis